Update from Attana's participation at the American Society for Virology’s (ASV) annual meeting
On July 19–23, 2021, Attana participated at the American Society for Virology’s (ASV) annual meeting to present the company and its newly CE-IVD-marked diagnostic kit and analytical instruments.
The ASV meeting was held virtually and participants shared information on the latest trends and current projects in the academic and government virology research community. There were more than 1,700 registered attendees, both potential customers and partners, who got the chance to visit Attana’s virtual booth and explore Attana’s offering within Life Science and Diagnostics.
Attana engaged in several interesting discussions during the conference and will follow up on these in the coming months as a part of its strategic plan to reactivate sales activities in North America.
For more information, please contact:
Teodor Aastrup, CEO
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact firstname.lastname@example.org